Compare Aurora Cannabis Inc (ACB) vs Nucor Corporation (NUE) Price & Performance

Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.

The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.

Nucor (NUE) trades at $227.42, up 3.02% over the past day, with a bearish technical signal despite recent earnings beats. The stock shows mixed sentiment with 59% analyst buy ratings but faces declining revenue and net income from 2022 peaks. Recent developments include a joint venture to support AI power infrastructure and a consistent dividend history, with Q2 2026 EPS guidance projecting growth.

Outlook remains cautiously optimistic due to strong analyst targets averaging $260.75 and operational expansions, though risks include steel demand volatility and compressed profit margins. The stock's valuation at a P/E of 22.21 appears reasonable if earnings rebound as projected in 2026.